Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

clonoSEQ testing for patients with diffuse large B-cell lymphoma (DLBCL ... and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during ...

For many decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. But, in recent years, a newer therapy in the form of immunotherapy has emerged, ...

after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma. The EMA’s human drugs advisory committee recommended approval of KTE-X19 (autologous anti-CD19-transduced CD3+ cells ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the first patient has been dosed in ...

Blood was tested for the presence of any remaining cancer cells using the clonoSEQ ... of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts ...

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...

that assesses diagnostic technologies through its Molecular Diagnostic Services Program (MolDX), has expanded coverage of clonoSEQ ® to include single time point testing to monitor for recurrence in ...

SEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...